GenomeDx Biosciences Inc. Secures Insurance Coverage for Decipher® Prostate Cancer Classifier
SAN DIEGO, Nov. 20, 2013 /PRNewswire/ -- GenomeDx Biosciences today announced that it has entered into contractual agreements for diagnostic laboratory testing as a participating provider with three separate private PPO Networks, bringing the Decipher® test to their networks of over 62.6 million covered lives. The three PPO networks are Stratose Inc., Three Rivers Provider Network and Fortified Provider Network.
"We are focusing on providing access to patients who can benefit from the Decipher test, which offers physicians and their patients actionable information from which to make informed decisions about the course of treatment after prostate surgery," said Doug Dolginow, MD, CEO of GenomeDx. "These agreements represent just the beginning of our efforts to engage payors. We are confident that patient access to Decipher will continue to improve as more insurance providers review the growing body of peer reviewed evidence demonstrating the ability of Decipher to accurately predict disease progression and direct treatment recommendations."
The Decipher® prostate cancer classifier directly measures the biological risk of metastatic prostate cancer. By assessing the activity of multiple genomic markers associated with metastatic disease, Decipher provides information about the aggressiveness of a patient's tumor - information distinct from that provided by PSA and other clinical tools. Through an extensive program of clinical studies, Decipher continues to demonstrate its ability to more accurately distinguish metastatic disease and impact treatment decisions for men with prostate cancer.
Decipher® is available to eligible US patients through their physicians and as a part of GenomeDx's ongoing program of clinical studies. To learn more about ordering the Decipher test please visit our website at www.genomedx.com.
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that impact treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. GenomeDx has developed the Decipher® prostate cancer classifier, the first and only commercially available genomic test that predicts the risk of developing metastatic prostate cancer independently of PSA and other conventional risk assessment tools. GenomeDx is based in San Diego, California and Vancouver, British Columbia.
SOURCE GenomeDx Biosciences